OMass Therapeutics is a biotechnology company developing novel small molecules for immunological and orphan diseases using proprietary biochemistry.

OMass is identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes. We are advancing a pipeline of small molecule therapeutics in orphan diseases and immunological conditions, targeting solute carriers, inflammasome complexes and GPCRs.

We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases.

2023年4月19日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs. Headquartered in Oxford, UK, OMass has raised over $150M (£119M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV ...

At OMass, we take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality.

2024年8月5日 · OMass has already made significant progress with its portfolio of highly-validated, yet intractable or inadequately drugged targets. OMass’ lead programme is an insurmountable antagonist of the GPCR MC2 receptor for Congenital Adrenal Hyperplasia which is expected to complete IND-enabling studies in 2025.

2025年2月26日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead programme is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and …

2024年11月15日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead programme is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and …

Jon has over 20 years’ experience in drug discovery in a wide variety of therapeutic areas including oncology, CNS, and metabolic disorders across a range of therapeutic modalities. Jon joined OMass Therapeutics from Nanna therapeutics, where he was Head of Chemistry, leading a portfolio of mitochondrial targeted programs to treat rare diseases.

2025年2月14日 · It is with heavy hearts that we remember our dear friend Prof. Graham Richards, a colleague, mentor and the first Chair of OMass, who passed away on Tuesday, February 11 th 2025. Graham was an influential academic and early advocate for translating research into enterprises where he believed it could impact wider society.